Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Ranok Therapeutics logo — Discovering next-gen therapies through targeted protein degr...

Ranok Therapeutics

Discovering next-gen therapies through targeted protein degradation for safer and more effective cancer treatment.

Founded 2018 Series B Total: $50.00M Biotechnology

General Information

Company Name Ranok Therapeutics
Founded Year 2018
Founders / Decision Makers
Team member
Industries Biotechnology
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Ranok Therapeutics. To contact Ranok Therapeutics, visit ranoktherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ranok Therapeutics compare?

A PDF of Ranok Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ranok Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ranok Therapeutics

Ranok Therapeutics is a biotechnology company founded in 2018 with a mission to discover next-generation therapies through targeted protein degradation, aiming to provide safer and more effective cancer treatment. The company's slogan "Discovering next-gen therapies through targeted protein degradation for safer and more effective cancer treatment" succinctly conveys its focus. Ranok Therapeutics distinguishes itself through pioneering advanced targeted protein degradation technology, leveraging various underlying biological mechanisms, and surpassing other approaches in the field. The company's pipeline includes both established and novel drug targets that address cancer and other diseases with significant unmet medical needs. This illustrates Ranok's commitment to creating the next generation of cancer therapies that are safer and more effective, establishing its focus on impactful innovation within the biotechnology industry. In August 2021, Ranok Therapeutics secured a significant $40.00M Series B investment from a consortium of notable investors including Wu Capital, Shanghai Healthcare Capital, Lapam Capital, and Zhongguancun Kaiyuan Capital. This investment underscores the confidence of these prominent investors in Ranok's potential for growth and impact within the biotechnology sector. Overall, Ranok Therapeutics' focus on targeted protein degradation for the development of innovative therapeutics, alongside its recent substantial Series B investment, positions the company as a significant player in the biotechnology industry, with potential for further advancements in cancer treatment and other medical needs.

Business keywords: targeted protein degradation, therapeutics, cancer treatment, innovation, drug discovery, biological mechanisms, pipeline development, unmet medical needs, next-generation therapies, effective treatments, safety in treatments

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $40.00M 4
Wu Capital Shanghai Healthcare Capital Lapam Capital
Wu Capital, Shanghai Healthcare Capital +2
19 Aug 2021
Seed Round $10.00M 3
LC Ventures Med-Fine Capital TF Capital
LC Ventures, Med-Fine Capital +1
27 Mar 2020

Ranok Therapeutics Alternatives & Competitors

View All Alternatives
Ranok Therapeutics vs
Amphista Therapeutics Limited
Amphista Therapeutics Limited United Kingdom

A new approach to targeted protein degradation to bring life-changing medicines to patients.

Series B
33 employees
Biopharma, Biotechnology
Ranok Therapeutics vs
Thelial Technologies
Thelial Technologies

Discovering and developing targeted carcinoma therapies through innovative drug discovery and reposi...

Grant
Biotechnology, Health Care
Ranok Therapeutics vs
PhoreMost Ltd
PhoreMost Ltd United Kingdom

Drugging the Undruggable®

Series B
33 employees
Biopharma, Biotechnology
Compare Ranok Therapeutics vs PhoreMost Ltd
View all alternatives

FAQ About Ranok Therapeutics

Discovering next-gen therapies through targeted protein degradation for safer and more effective cancer treatment.
Ranok Therapeutics was founded in 2018.
Ranok Therapeutics operates in Biotechnology. Its work centres on targeted protein degradation, therapeutics, cancer treatment and innovation.
Ranok Therapeutics has completed 2 funding rounds, raising a total of $50.00M. The latest funding stage is Series B.
Top alternatives and competitors to Ranok Therapeutics include Amphista Therapeutics Limited, Thelial Technologies, PhoreMost Ltd, Zymeworks Inc., Orum Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ranok Therapeutics and Amphista Therapeutics Limited are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ranok Therapeutics, https://bouncewatch.com/company/ranok-therapeutics, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout